Raffaella Bosco

984 total citations
17 papers, 610 citations indexed

About

Raffaella Bosco is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Raffaella Bosco has authored 17 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Raffaella Bosco's work include Chronic Lymphocytic Leukemia Research (5 papers), Cytomegalovirus and herpesvirus research (5 papers) and Viral-associated cancers and disorders (4 papers). Raffaella Bosco is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Cytomegalovirus and herpesvirus research (5 papers) and Viral-associated cancers and disorders (4 papers). Raffaella Bosco collaborates with scholars based in Italy, Germany and United States. Raffaella Bosco's co-authors include Giorgio Zauli, Paola Secchiero, Claudio Celeghini, E. Melloni, Rebecca Voltan, Federica Corallini, Sabrina Ingrao, Sonia Zorzet, Claudio Tripodo and Barbara Zavan and has published in prestigious journals such as PLoS ONE, Journal of Virology and Clinical Cancer Research.

In The Last Decade

Raffaella Bosco

17 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raffaella Bosco Italy 10 338 279 143 109 97 17 610
Zahra Asgari United States 9 316 0.9× 207 0.7× 42 0.3× 126 1.2× 68 0.7× 16 537
Mohammad Krayem Belgium 16 290 0.9× 414 1.5× 128 0.9× 111 1.0× 35 0.4× 27 716
Beate Alinger Austria 19 192 0.6× 490 1.8× 49 0.3× 152 1.4× 45 0.5× 23 734
Alice Cani Italy 14 126 0.4× 394 1.4× 105 0.7× 121 1.1× 75 0.8× 26 645
Renata Duchnowska Poland 18 719 2.1× 309 1.1× 187 1.3× 155 1.4× 31 0.3× 68 1.1k
Ester Alvino Italy 17 189 0.6× 500 1.8× 54 0.4× 280 2.6× 43 0.4× 35 813
Giulia Spallone Italy 12 136 0.4× 237 0.8× 44 0.3× 72 0.7× 62 0.6× 27 609
Raymond Beaulieu Canada 9 388 1.1× 359 1.3× 72 0.5× 161 1.5× 39 0.4× 15 744
Yvette van Hensbergen Netherlands 12 348 1.0× 301 1.1× 55 0.4× 155 1.4× 37 0.4× 22 666
Michael A. Damore United States 16 276 0.8× 302 1.1× 68 0.5× 48 0.4× 45 0.5× 30 775

Countries citing papers authored by Raffaella Bosco

Since Specialization
Citations

This map shows the geographic impact of Raffaella Bosco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffaella Bosco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffaella Bosco more than expected).

Fields of papers citing papers by Raffaella Bosco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffaella Bosco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffaella Bosco. The network helps show where Raffaella Bosco may publish in the future.

Co-authorship network of co-authors of Raffaella Bosco

This figure shows the co-authorship network connecting the top 25 collaborators of Raffaella Bosco. A scholar is included among the top collaborators of Raffaella Bosco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffaella Bosco. Raffaella Bosco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Facchinetti, Fabrizio, Nadia Moretto, Paola Caruso, et al.. (2014). In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile. European Respiratory Journal. 44(Suppl 58). 4860–4860. 1 indexed citations
2.
Bala, Kiran, Raffaella Bosco, Silvia Gramolelli, et al.. (2012). Kaposi's Sarcoma Herpesvirus K15 Protein Contributes to Virus-Induced Angiogenesis by Recruiting PLCγ1 and Activating NFAT1-dependent RCAN1 Expression. PLoS Pathogens. 8(9). e1002927–e1002927. 47 indexed citations
3.
Voltan, Rebecca, Maria Grazia di Iasio, Raffaella Bosco, et al.. (2011). Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research. 17(17). 5649–5655. 18 indexed citations
4.
Zauli, Giorgio, Rebecca Voltan, Maria Grazia di Iasio, et al.. (2011). miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells. Clinical Cancer Research. 17(9). 2712–2724. 63 indexed citations
5.
Secchiero, Paola, Raffaella Bosco, Claudio Celeghini, & Giorgio Zauli. (2011). Recent Advances in the Therapeutic Perspectives of Nutlin-3. Current Pharmaceutical Design. 17(6). 569–577. 133 indexed citations
6.
Zauli, Giorgio, Raffaella Bosco, & Paola Secchiero. (2011). Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opinion on Therapeutic Targets. 15(8). 931–942. 4 indexed citations
7.
Bosco, Raffaella, E. Melloni, Claudio Celeghini, et al.. (2011). Fine Tuning of Protein Kinase C (PKC) Isoforms in Cancer: Shortening the Distance from the Laboratory to the Bedside. Mini-Reviews in Medicinal Chemistry. 11(3). 185–199. 45 indexed citations
8.
9.
Zauli, Giorgio, Rebecca Voltan, Raffaella Bosco, et al.. (2010). Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. Clinical Cancer Research. 17(4). 762–770. 41 indexed citations
10.
Secchiero, Paola, Federica Corallini, G. Castellino, et al.. (2010). Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. The Journal of Rheumatology. 37(7). 1461–1466. 8 indexed citations
11.
Bosco, Raffaella, Marco Rabusin, Rebecca Voltan, et al.. (2010). Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells. Investigational New Drugs. 30(1). 417–422. 5 indexed citations
12.
Secchiero, Paola, Sonia Zorzet, Claudio Tripodo, et al.. (2010). Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE. 5(6). e11140–e11140. 125 indexed citations
13.
Barozzi, Patrizia, Leonardo Potenza, Giovanni Riva, et al.. (2008). Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of Iatrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis. Seminars in Arthritis and Rheumatism. 39(3). 170–175. 7 indexed citations
14.
Barozzi, Patrizia, Chiara Bonini, Leonardo Potenza, et al.. (2008). Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma. Transplantation. 86(5). 738–744. 51 indexed citations
15.
Barozzi, Patrizia, Leonardo Potenza, Giovanni Riva, et al.. (2007). B cells and Herpesviruses: A model of lymphoproliferation. Autoimmunity Reviews. 7(2). 132–136. 21 indexed citations
16.
Guaraldi, Giovanni, Stefania Cocchi, Mauro Codeluppi, et al.. (2006). Giant cell hepatitis following primary infection with HHV-6 variant A, transmitted from the donor, in a liver transplant recipient latently infected with HHV-6 variant B. 37. 1 indexed citations
17.
Guaraldi, Giovanni, Stefania Cocchi, Mauro Codeluppi, et al.. (2006). 40: Giant cell hepatitis following primary infection with HHV-6 variant A, transmitted from the donor, in a liver transplant recipient latently infected with HHV-6 variant B. Journal of Clinical Virology. 37. S108–S108. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026